Immunogenicity of Multiple Antigenic Peptides (MAP) Based on B and T cell Epitopes of E2 Glycoprotein of Chikungunya Virus in Murine System

Nagar PK¹, Manmohan P², Kolli VK³ and Rao DN*¹

¹Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, India
²Divisions of Virology, Defense Research & Development Establishment (DRDE), Gwalior, India
³Department of Biochemistry, GITAM Institute of Medical Sciences & Research (GIMSR), Visakhapatnam, India

*Corresponding author: Rao DN, Professor and Head (Retd.), Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India, Tel: +91 9868592706, E-mail: dnrao311@rediffmail.com

Citation: Nagar PK, Manmohan P, Kolli VK, Rao DN (2017) Immunogenicity of Multiple Antigenic Peptides (MAP) Based on B and T cell Epitopes of E2 Glycoprotein of Chikungunya Virus in Murine System. J Immunol Infect Dis 4(2): 201

Abstract

Objective: Chikungunya is a viral disease caused by positive sense single stranded RNA virus. High fever, myalgia, arthralgia, body rashes are the characteristic features of Chikungunya transmitted by Aedes mosquitoes. We aim to demonstrate that dominant epitopes of envelope E2 protein can be used for diagnostic purposes as well as vaccine design.

Methods: Multiple Antigenic Peptide (MAP) approach was used based on B and T cell epitopes of E2 protein. Humoral and cell mediated responses were studied in outbred and inbred H-2¹ mice. Different groups of mice were immunized intramuscularly with or without adjuvant (CpG ODN and murabutide) in PLGA microspheres.

Results: MAP entrapped in microspheres with CpG ODN showed highest IgG peak titer (2,98,000) with IgG subclass, mostly IgG2a/2b distribution. MAP's antisera showed significant immunoreactivity with individual peptides. During thymidine incorporation assay for T cells, all the MAPs showed high lympho-proliferative response. Cytokine profile was dominated by Th1 and Th17 response. Thus, all the MAPs showed high humoral and cell mediated response with CpG/ murabutide adjuvant. MAP's antisera showed significant in vitro neutralization of CHIKV strain in vero cells.

Conclusion: MAP appears to be an alternate approach for vaccine design.

Keywords: Multiple Antigenic Peptide; B and T cell Response; Chikungunya; E2 protein

Introduction

Chikungunya is a febrile illness caused by positive sense RNA virus that belongs to genus Alphavirus of the Togaviridae family. Chikungunya virus (CHIKV) is an enveloped virus with four non-structural (nsP1–4) and five structural proteins (C, E1–3, 6K) [1]. First time Chikungunya disease was identified in East Africa in the early 1952 [2,3]. CHIKV symptoms start 4 to 7 days after exposure and mostly resolve within two weeks of acute phase. Although the acute phase lasts approximately 2 weeks, joint pain can persist for months or even years following initial infection [4,5]. Currently there is no licensed vaccine or effective therapy available for prevention or treatment of CHIKV. However, efficacy of recombinant and attenuated vaccine was tried in murine and primate models through the generalization of neutralizing antibodies [6-10]. We focused our attention on E2 glycoprotein because of its involvement in host-cell receptor interaction with immune cells [11]. Thus, it can be a good target for virus neutralization/ blocking antibody for receptor on the antigen presenting cells by the virus. Previous studies showed that monoclonal antibody against the specific epitope of E2 protein protected mice or inhibited virus entry inside the vero cells after CHIKV challenge [12-15]. These observations prompted us to use B and T cell epitopes of E2 protein in developing MAP based immunogen. We identified few dominant epitopes on E2 protein based on murine data and reactivity with convalescent human sera [16-18]. T cell epitopes were identified on the basis of in vitro T cell proliferation and cytokines profile [17,18]. In the present study, these epitopes were assembled together as a MAP construct for designing immunogen for CHIKV. MAP allows the incorporation of multiple copies of a single or different epitopes in a defined manner. Previous studies showed improved immune response can be achieved for different disease using MAP approach [19-21]. MAP entrapped in PLGA microspheres with CpG ODN or Murabutide adjuvant
showed high antibody titers and produced virus neutralizing antibody in vitro. MAP also showed cell mediated immune response in terms of high stimulation index and generated protective or beneficial cytokines. Thus, assembling as a MAP proved to be a better immunogen.

**Methods**

**Synthesis of multiple antigenic peptides (MAP)**

Dominant B and T cell epitopes of E2 protein were constructed as MAPs using Fmoc chemistry. Three MAPs viz. MAP-1, MAP-2, MAP-3 were synthesized on Gly-HMP-Tantageyl resin [21]. All the MAPs were purified by HPLC and characterized by amino acid analysis and molecular weight. Following MAPs were constructed with different B and T cell epitopes.

![Diagram of MAPs](image)

**Experimental Mice**

Six to eight weeks old outbred and BALB/c (H-2d) mice were used. Six to eight mice were used in each group. Experiments were done according to the guidelines of AIIMS Ethics as well as CPCSEA, Ministry of Social Justice, Government of India.

**Entrapment of MAPs in PLGA microparticle, particle size and morphology**

MAPs were entrapped in microspheres using poly (DL-lactide-co-glycolide; 50:50) (Sigma, USA) by double solvent evaporation method (water-in-oil-in-water) [22]. Percentage of entrapment of MAPs in microspheres was estimated by bicinchoninic acid (BCA) method (Sigma, IL, USA) and it was in the range of 53-64%. The size was between 2-8 µm. Morphology of microspheres was found to be spherical.

**Immunization of mice and Sera collection**

PLGA microspheres containing 40µg of MAPs was dissolved in 40 µl of PBS with 5µg CpG-ODN 1826 (TCCATGACGTTCCTGACGTT) (Coley Pharmaceuticals, USA) or murabutide (Invivogen,USA) adjuvants. Different group of mice were immunized intramuscularly with MAPs in microspheres (MS), MAPs in MS with 5µg of CpG ODN and MAPs in MS with 5µg of murabutide at the thigh region on day 0. Booster dose of 20µg of MAPs with 5µg of adjuvants was given on days 23 and 42. 0.5 ml blood was collected from retroorbital plexus on the days 28, 42, 60, 90, 120. Antisera was separated and stored at −20 °C till use.

**Reactivity of MAP with E2 antisera and MAP antisera with their respective peptides and E2 protein**

MAP’s reactivity with E2 protein antisera were tested by direct binding assay. ELISA plates were coated with different MAPS (100ng/well). Plates were blocked with 5% milk powder and washed with 0.05% of PBS tween-20. The antisera raised with E2 protein in outbred mice was added at a dilution of 1:200 onto the ELISA plates and incubated at 37 °C for 2h. In the same manner, reactivity of individual peptides with MAPs antisera was also tested. Plates were coated with respective peptides (200ng/well) and incubated with MAPs antisera with two-fold serial dilution and incubated at 37 °C for 2 h. To check the reactivity of MAPs with peptide antisera, plates were coated with different MAPs (200ng/well) and incubated with different peptide antisera at a dilution of 1:200 and incubated at 37 °C for 2 h. After washing, goat anti-mouse IgG-HRP (1:1000 dilutions) was added and kept at 37 °C for 1 h and color was developed using OPD as a chromogen and H₂O₂ as a substrate [23].

**Humoral response (Peak antibody levels)**

MAP specific antibody levels were estimated using standard ELISA protocol. Briefly, 96 well microtiter plates (Immuno II HB, Dynatech) were coated with 200 ng/well of each MAP (100 µl/well), non-specific binding sites were blocked with 5% milk powder. After washings, serial two-fold dilution of different MAP antisera was added to measure IgG peak antibody titers. Color was developed as described above. The titers were expressed as the highest serum dilution giving an absorbance higher than that of pre-immune sera.
**Estimation of IgG subclass**

IgG subclass (IgG1, IgG2a, IgG2b and IgG3) estimation was done as per manufacturer’s instructions using isotyping kit ISO-2 (Sigma, USA). 100 ng/well of MAP were coated on ELISA plates and MAP pooled sera of each group was added at 1:200 dilution and color was developed as described above.

**Memory response**

To check the memory or amnestic response, mice were immunized with 20µg of native E2 protein with 5µg CpG ODN on day 120 and bleeds were collected on day 135 and IgG antibody titers were estimated as described above.

**In vitro T cell proliferation assay**

Microspheres containing the respective MAPs were injected intramuscularly to outbred and inbred H-2d mice with a primary dose of 40µg MAP equivalent on day 0 with 5µg CpG ODN/ Murabutide. Booster dose of 20µg of respective MAP and 5µg CpG/Murabutide was given on day 10. In case of E2 protein, mice were immunized with primary dose of 30µg with 5µg CpG ODN on day 0 followed by booster dose of 15µg + 5µg CpG ODN on day 10. Splenocytes (devoid of B cells by panning with anti-mouse immunoglobulin) were cultured in triplicate wells(2x10^5 cells/well) on day 21 in RPMI 1640 medium (300 µl/well) containing the appropriate antibiotics. Following variables were used to stimulate splenocytes.

1. Splenocytes were primed with E2 protein in vivo and in vitro stimulated with native E2 protein (5,10 and 25 µg/well) or with individual MAPs (10, 25, 50µg/well).
2. Splenocytes were primed with individual MAPs in vivo and in vitro stimulated with native E2 protein and cognate MAP (10, 25, and 50µg/well).

PHA (2 µg/well) was used as positive control. After 72 h of culture, 200µl of culture supernatant was collected from each well and stored at −70°C for cytokine estimation. The cultures were pulsed with [³H] thymidine 0.5µCi/well and after 18h, cells were harvested. Thymidine incorporation was measured by a liquid β scintillation counter. Stimulation index (SI) was calculated. The data was presented as mean SI±SD of triplicate wells.

**Cytokine level measurement**

The levels of Th1, Th2, Th17 and pro-inflammatory (IL-1β, IL2, IL-4, IL-10, IL-12, IL-17, TNF-α, IFN-γ) cytokines were measured in the culture supernatant using sandwich ELISA (e-Biosciences). Data was presented as mean concentration of cytokine (pg/mL) ± S.D. of triplicate wells.

**Neutralization assays**

90% plaque reduction neutralization test (PRNT_{90}) in vero cells was done by reported procedure using two-fold serial dilution of MAPs antiserum.(23) Plaque was counted and titers were calculated and expressed as the reciprocal of serum dilution yielding ≥90% reduction (PRNT_{90}) in the number of plaques.

**Statistical analysis**

The data on MAPs specific IgG, IgG subclass, T cell proliferation and cytokine levels were compared by non-parametric Kruskal-Wallis one-way analysis of variance by ranks. The levels of significance (p value) were compared between different formulations of MAPs & Mean antibody titers in sera were compared with student’s t- test.

**Results**

**Antibody peak titer of MAPs antisera at different intervals**

All the MAPs were found to be immunogenic and showed high IgG titers with all formulations on days 28, 42, 60, 90 and 120. MAP entrapped in microspheres (MS) showed serum IgG titers ranging from 90,000 to 1,70,000 in outbred and H-2d mice respectively (Figure 1A and Supplementary 1A). MAP with murabutide showed antibody titer ranging from 1,75,000 to 1,82,000 (Figure 1B and Supplementary 1B) and MAP with CpG showed antibody titers ranging from 2,50,000 to 2,98,800 in both strain of mice (Figure 1C and Supplementary 1C). Among all formulations used, MAP+CpG formulation showed significantly (p<0.0001) high serum IgG titers in both strains of mice. With all formulations irrespective of strains used, maximum titers were observed on day 60 which was maintained until day 90 with gradual decline on day 120. Overall MAP+CpG showed significantly (p<0.0001) higher peak antibody levels followed by MAP+Murabutide and MAP in microspheres in both strains of mice.

**Individual peptides and E2 protein reactivity with MAPs antisera, MAPs reactivity with E2 protein antisera**

MAPs response to individual peptides was measured in mice in terms of peak antibody titer on 60th day. Antisera generated
with MAP + CpG formulation was found to be significant (p<0.05) in terms of peak antibody titre in outbred mice. Peptide E2P5 of MAP-1 showed highest endpoint titer as compared to other peptides. Peptides E2P5 showed maximum peak antibody titers upto 1,10,000, E2P3 of MAP-2 showed 1,25,000, E2P10 and E2P16 of MAP-3 showed 1,00,000 and 122000 peak antibody titers respectively (Figure 2C). Similar observation was seen in H-2^d mice too (Figure S2B). The E2 protein showed significant (P<0.001) immunoreactivity with MAP1-3 antisera on day 60 of outbred and H-2^d mice (Figure 2B and Supplementary 2A & B). The study concludes that all the MAPs induced antibodies to different epitopes of E2. In vice versa MAP1-3 also showed significant immunoreactivity with E2 antisera (Figure 2A).

IgG subclasses estimation in antisera

Isotyping was done for antisera of outbred and inbred mice. In case of outbred mice, IgG2a/IgG2b antibody levels were significantly
high (P<0.001) for MAP-1, 2. While MAP-3 showed equal distribution of IgG1 and IgG2a/IgG2b subtypes (Table 1A). The isotypes ratio (IgG2a/IgG1) was found to be >1.0 with MAP+CpG formulation for MAP-1 and MAP-2 showing Th1 dominant immune response. MAP-3 showed isotypes ratio ≤1 thereby showed a mixed Th1/Th2 response. The maximum isotype levels were observed on day 60 sera. Similar isotype pattern was observed in inbred H-2^d strain (Table 1B).

### Table 1A

| MAP      | IgG subclass | 42 day | 60 day | 90 day | 135 day |
|----------|--------------|--------|--------|--------|---------|
| MAP-1    | IgG1         | 0.488* | 0.692  | 0.589  | 0.692   |
|          | IgG2a        | 1.498* | 1.745* | 1.164* | 1.769*  |
|          | IgG2b        | 1.262* | 1.932* | 1.378* | 1.695*  |
| MAP-2    | IgG1         | 0.501* | 0.645  | 0.568  | 0.689   |
|          | IgG2a        | 1.091* | 2.167* | 1.467* | 2.346*  |
|          | IgG2b        | 1.340* | 2.094* | 1.562* | 2.290*  |
| MAP-3    | IgG1         | 1.002  | 1.167  | 1.023  | 1.580   |
|          | IgG2a        | 1.109  | 1.542  | 1.132  | 1.532   |
|          | IgG2b        | 1.245  | 1.564  | 1.145  | 1.450   |

*indicates p< 0.001 compared to IgG1antibody levels.

### Table 1B

| MAP      | IgG subclass | 42 day | 60 day | 90 day | 135 day |
|----------|--------------|--------|--------|--------|---------|
| MAP-1    | IgG1         | 0.570  | 0.769  | 0.406  | 0.567   |
|          | IgG2a        | 1.124* | 1.890* | 1.284* | 1.680*  |
|          | IgG2b        | 0.949* | 2.189* | 1.432* | 1.721*  |
| MAP-2    | IgG1         | 0.501  | 0.745  | 0.512  | 0.490   |
|          | IgG2a        | 1.456* | 2.230* | 2.007* | 2.452*  |
|          | IgG2b        | 1.280* | 2.189* | 1.601* | 2.219*  |
| MAP-3    | IgG1         | 1.128  | 1.452  | 1.210  | 1.645   |
|          | IgG2a        | 1.245  | 1.396  | 1.189  | 1.452   |
|          | IgG2b        | 1.321  | 1.564  | 1.245  | 1.521   |

* indicates p<0.001 compared to IgG1antibody levels.

### In vitro T cells proliferation

Out of the four MAPs showed higher stimulation index (SI) during in vitro stimulation of splenocytes. E2 primed splenocytes of outbred mice when stimulated with different MAPs, MAP-2 showed highest stimulation index. All the MAPs showed stimulation index in the range 30±1.23 to 41±2.87. Similarly, stimulation of MAP primed splenocytes of outbred mice with respective MAPs, MAP-1, MAP-3 showed stimulation index 36±4.89, 38±5.12 at 25µg/well while MAP-2 showed 45±3.45 at 25µg/well respectively (Fig.3A). E2/MAPs primed splenocytes of inbred mice when stimulated with MAPs also showed high stimulation index 30±1.23, 34±4.89, and 43±5.12 (Figure S2C). Results indicate that all the MAPs generated high lymphoproliferative response in outbred and inbred mice, while MAP-2 appears to be a superior construct over others.

### Memory response

B-cell memory response is a necessary feature to develop a vaccine as memory helps in quick antibody synthesis and clearance of infection on re-exposure to the pathogen. Amnestic response was confirmed by giving a booster with E2 protein on day 120 and response was evaluated on day 135 for all the MAPs. They showed memory response through generation of high antibody levels on days 42, 60, 90 and 135.

### Cytokines’ levels

MAP-1, MAP-2 and MAP-3 showed significantly (p<0.01) high IL-1β, IL-12, IL-2 and IL-17A cytokine levels when CpG was used as an adjuvant. The levels of IL-1β, IL-2, IL-12 and IL-17A cytokines were found to be significant with a range of 1022-1208 pg/mL (p<0.005), 160-196pg/mL (p<0.001), 250-325 pg/mL, (p<0.05) and 184-298 pg/mL (p<0.001) respectively (Table 1B). MAP-1 and MAP-2 produced significantly high IFN-γ (1480, 1345 pg/mL, p<0.001) followed by MAP-3 (970pg/mL, p<0.05) when compared to unstimulated cells (189pg/mL) (Table 2). IL-4 levels were comparatively less (P<0.001) with MAP-1 & MAP-2 while MAP-3 has moderate levels (Table 2). However, IL-10 levels were insignificant for all the MAPs (Table 2). Significantly high (P<0.005) levels of TNF-α was observed for MAP-1, MAP-2 and MAP-3 (Table 2). IL-1β, TNF-α, IFN-γ cytokines level of MAP primed splenocytes stimulated with cognate MAP was in the range 1202-1480 pg/mL (P<0.001), 189-240 pg/mL (P<0.001), 1275-1489 pg/mL (P<0.001) respectively. Rest of the cytokines levels were in the same range (Table 2).

### Table 2

| Peptides | IL-1β | IL-4 | IL-6 | IL-10 | IL-12 | IL-17 | TNF-α | IFN-γ |
|----------|-------|------|------|-------|-------|-------|-------|-------|
| MAP-1    | 1208±28.6 | 50±0.45 | 45±4.67 | 325±5.69 | 184±12.8 | 198±5.56 | 1480±18.6 |
| MAP-2    | 1109±6.81  | 65±7.10 | 38±2.89 | 300±2.89 | 254±7.98 | 158±9.00 | 1345±5.89 |
| MAP-3    | 1022±14.8 | 155±5.89 | 52±2.09 | 250±8.90 | 298±5.89 | 160±1.69 | 970±9.90 |
| E2 protein | 378±1.89 | 164±12.0 | 234±5.90 | 440±5.86 | 90±4.68 | 89±14.9 | 1720±16.8 |

Maps primed splenocytes stimulated with cognate MAPs
In case of inbred mice E2 primed splenocytes stimulated with MAPs, IL-4 level for MAP-3 was 208 pg/mL compared to unstimulated cells 49 pg/mL. MAP-1, 2 produced significantly high IL-17 \((p < 0.005)\) followed by MAP-3 \((p < 0.001)\) as compared to unstimulated cells (Table S2). IFN-γ levels for MAP1-3 were 1210-1689 pg/mL compared to unstimulated cells 192 pg/mL (Table S1). Finally results conclude that MAP 1-3 showed significantly high level of IL-1β, IL-2, IL-12, IL-17, TNF-α, IFN-γ while IL-4 and IL-10 levels were significantly less in culture supernatants of both outbred and inbred strains.

**In vitro neutralization assay**

Plaque reduction neutralization (PRNT\(_{90}\)) assay was performed to validate the neutralizing capacity of MAPs specific antisera against CHIKV. MAP + CpG antiserum of day 60 was used for in vitro neutralizing assay. Antisera of MAP-2 at 1:4000, MAP-1 at 1:2000 and MAP-3 at 1:500 dilutions showed 90% inhibition of CHIK virus multiplication in vero cells (Figure 3A). E2 protein sera showed inhibition at 1:3000 dilutions (Figure 3B).

**Table 2:** Cytokine levels in culture supernatant of splenocytes of outbred mice. Cultures were obtained when E2 protein primed splenocytes were stimulated with E2 protein or MAPs

| Peptides | IL-1β | IL-2 | IL-4 | IL-10 | IL-12 | IL-17 | TNF-α | IFN-γ |
|----------|-------|------|------|-------|-------|-------|-------|-------|
| MAP-2    | 1480±18.4 | 156±2.89 | 39±6.45 | 49±8.96 | 319±2.89 | 268±12.8 | 254±6.89 | 1489±12.6 |
| MAP-3    | 1202±7.89 | 198±12.9 | 165±5.42 | 56±5.45 | 240±3.90 | 360±10.8 | 189±9.08 | 1275±2.89 |
| 1EM      | 392±8.90 | 38±7.89 | 45±1.90 | 42±2.19 | 102±4.50 | 62±5.90 | 60±2.89 | 189±5.45 |

Data are representative of two independent experiments and are shown as Mean ± SD

1EM – Empty microspheres

**Discussion**

Peptide based immunogen are easy to synthesize and safe to use but its low molecular weight, high degradability and short half-
life generally induce low immunogenicity [24,25]. MAPs’ approach can be a better option for peptide based immunogens without a carrier molecule and to avoid genetic restriction. In this study different formulation of MAPs were used, MAP entrapped in microspheres with CpG ODN showed highest peak antibody titers and sustained over longer duration with strong memory response after boosting with native protein, followed by MAP + murabutide formulation as compared to without adjuvant. When MAP’s antisera were tested with individual peptides, all peptides showed immunoreactivity with little variation, while few peptides showed dominance. These results prove that MAPs polyclonal antisera have different levels of peptide specific antibodies. IgG2a/ IgG2b were found to be highest (P<0.05) for MAP-1 and MAP-2 while MAP-3 showed equal distribution of IgG1 and IgG2a/IgG2b subclass. IgG2a and IgG2b antibodies are cytophilic in nature and are involved in protection. However, in case of CHIKV IgG1 and IgG2b subtype antibodies are found to be important in protection [26,27]. Further, MAP with CpG ODN showed enhanced T cell response. Cytokine profile showed Th1 and Th17 response which is known to be beneficial to the host. To understand the induced cell mediated immune response due to MAPs, cytokine profiles (Th1, Th2 and Th17) were measured. Tumor Necrosis Factor (TNF-α) and IL-1β cytokine produced by macrophage/ monocytes during acute inflammation play an important role in the activation of innate and adaptive immunity [26,28]. Tumor Necrosis Factor (TNF-α) and IL-1β cytokine play an important role in the activation of innate and adaptive response during pathogenic condition [28,29]. In the present study, all the MAPs showed significantly higher levels of IL-1β and TNF-α, but these levels were comparatively low with E2 protein. This could be due to the presence of immunosuppressive epitopes on E2 protein. Thus, MAPs induced high CMI response by producing pro-inflammatory cytokines such as IL-1β and TNF-α. The present study showed higher production of IFN-γ with MAP-1, MAP-2, MAP-3. This indicates that IFN-γ definitely has protection against CHIKV in agreement to an earlier study [30]. The levels of IL-4 cytokine were comparatively higher for MAP3 and E2 while MAP-1, MAP-2 showed Th1 and MAP-3 showed mixed Th1/Th2 type response. Only E2 protein showed high levels of IL-10 cytokine. Because IL-10 is considered to be immunosuppressive and can cause termination of inflammatory response [31]. Another important cytokine IL-17 play protective roles in host defense against certain pathogens at epithelial and mucosal barriers and promote the up regulation of other inflammatory cytokines and chemokines [31]. In the present study, IL-17 level was significantly higher for MAP-1, MAP-2, MAP-3 but E2 could not generate significant levels of IL-17, thus MAPs can activate different cell lineages of immune system to clear CHIKV infection. Most important feature for antibody is in vitro neutralization of CHIKV virus multiplication in vero cells. When CHIKV infects the host in the presence of the neutralizing antibodies, the viral clearance is very fast [12,14]. All the MAPs showed high antibody peak titer, in vitro T cell proliferation with significant level of protective cytokines and virus neutralization. These are important criteria for a good vaccine. Thus, MAPs can be an alternate option for developing subunit vaccine for CHIKV.

Conclusion

Constructed MAPs derived for E2 protein based on B and T cell epitopes showed enhanced B and T cell response in murine model. MAPs induced high IgG antibody titer in outbred and H-2d mice. IgG2a/IgG2b Isotypes were dominant for MAP-1, MAP-2 while MAP-3 showed equal distribution of IgG1 and IgG2a/IgG2b isotypic antibodies. MAP-1 and MAP-2 showed high T cell response. Cytokine profile showed Th1 and Th17 response which is known to be beneficial to the host. To understand the induced cell mediated immune response due to MAPs, cytokine profiles (Th1, Th2 and Th17) were measured. Tumor Necrosis Factor (TNF-α) and IL-1β cytokine produced by macrophage/ monocytes during acute inflammation play an important role in the activation of innate and adaptive immunity [26,28]. Tumor Necrosis Factor (TNF-α) and IL-1β cytokine play an important role in the activation of innate and adaptive response during pathogenic condition [28,29]. In the present study, all the MAPs showed significantly higher levels of IL-1β and TNF-α, but these levels were comparatively low with E2 protein. This could be due to the presence of immunosuppressive epitopes on E2 protein. Thus, MAPs induced high CMI response by producing pro-inflammatory cytokines such as IL-1β and TNF-α. The present study showed higher production of IFN-γ with MAP-1, MAP-2, MAP-3. This indicates that IFN-γ definitely has protection against CHIKV in agreement to an earlier study [30]. The levels of IL-4 cytokine were comparatively higher for MAP3 and E2 while MAP-1, MAP-2 showed Th1 and MAP-3 showed mixed Th1/Th2 type response. Only E2 protein showed high levels of IL-10 cytokine. Because IL-10 is considered to be immunosuppressive and can cause termination of inflammatory response [31]. Another important cytokine IL-17 play protective roles in host defense against certain pathogens at epithelial and mucosal barriers and promote the up regulation of other inflammatory cytokines and chemokines [31]. In the present study, IL-17 level was significantly higher for MAP-1, MAP-2, MAP-3 but E2 could not generate significant levels of IL-17, thus MAPs can activate different cell lineages of immune system to clear CHIKV infection. Most important feature for antibody is in vitro neutralization of CHIKV virus multiplication in vero cells. When CHIKV infects the host in the presence of the neutralizing antibodies, the viral clearance is very fast [12,14]. All the MAPs showed high antibody peak titer, in vitro T cell proliferation with significant level of protective cytokines and virus neutralization. These are important criteria for a good vaccine. Thus, MAPs can be an alternate option for developing subunit vaccine for CHIKV.

Acknowledgements

Authors are thankful to Defence Research and Development Organization (DRDO) and Department of Science and Technology (DST) for financial support. Mr. Pradeep Kumar Nagar is thankful to Department of Biotechnology (DBT) for his fellowship.

Supplementary Information

References

1. Jose J, Snyder JE, Kuhn RJ (2009) A structural and functional perspective of alphavirus replication and assembly. Future Microbiol 4: 837-56.
2. Suhrbier A, Jaffar-Bandjee, MC, Gasque P (2012) Arthritogenic alphaviruses—an overview. Nat Re Rheumatol 8: 420-9.
3. Robinson MC (1955) An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg. 49: 28-32.
4. Schilte C, Staikowsky F, Couldec T, Madec Y, Carpentier F, et al. (2013) Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis 7: e2137.
5. Sissoko D, Malvy D, Edzede K, Renault P, Moscetti F, et al. (2009) Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis 3: e389.
6. Garcia-Arriaza J, Cepeda V, Hallengard D, Sorzano CO, Kummerer BM, et al. (2014) A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol 88: 3527-47.
7. Roy CJ, Adams AP, Wang E, Plante K, Gorchakov R, et al. (2014) Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 209: 1891-9.
8. Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, et al. (2012) Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med 4: 330-43.
9. Tretyakova I, Hearn J, Wang E, Weaver S, Pushko P (2014) DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis 209: 1882-90.
10. Hallengard D, Kakoulidou M, Lulla A, Kummerer BM, Johansson DX, et al. (2014) Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol 88: 2858-66.
11. Smith TJ, Cheng RH, Olson NH, Peterson P, Chase E, et al. (1995) Putative receptor binding sites on alphaviruses as visualized by cryoelectron microscopy. Proc Natl Acad Sci USA 92: 10648-52.
12. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, et al. (2013) Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog 9: e1003312.
13. Chua CL, Chan YF, Sam IC (2014) Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein. J Virol Methods 195: 126-33.
14. Lum FM, Teo TH, Lee WW, Kam YW, Renia L, et al. (2013) An essential role of antibodies in the control of Chikungunya virus infection. J Immunol 190: 6295-302.
15. Goh LYH, Hobson-Peters J, Prow NA, Gardner J, Bielefeldt-Ohmann H, et al. (2013) Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clin Immunol Orlando Fla 149: 487-97.
16. Verma P, Bhatnagar S, Kumar P, Chattree V, Parida MM, et al. (2014) Analysis of antibody response (IgM, IgG, IgG3) to Chikungunya virus using panel of peptides derived from envelope protein for serodiagnosis. Clin Chem Lab Med 52: 297-307.
17. Nagar PK, Pradhan S, Verma P, Joshi G, Amrita Singh, et al. (2016) Mapping and Immunological Response of Immunodominant B and T cell Epitopes of E2 Glycoprotein of Chikungunya Virus. MOJ Immunol 4: 1-10.
18. Nagar PK, Gupta DL, Parida MM, Rao DN (2016) Identification of immunodominant epitopes of e1 and nucleocapsid proteins of chikungunya virus with neutralizing capacity. Int J Curr Med & Pharma Res 2: 898-905.
19. Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA (2005) Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 54: 107-19.
20. Oscherwitz J, Yu F, Cease KB (2009) A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen. Infect Immun 77: 5509-18.
21. Uppada SB, Bhat AA, Sah A, Donthamshetty RN (2011) Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice. Vaccine 29: 9352-60.
22. Ali R, Kumar S, Naqvi RA, Rao DN (2013) B and T cell epitope mapping and study the humoral and cell mediated immune response to B-T constructs of YscF antigen of Yersinia pestis. Comp Immunol Microbiol Infect Dis 36: 439-51.